Olaf Weber

2.0k total citations
34 papers, 1.3k citations indexed

About

Olaf Weber is a scholar working on Epidemiology, Immunology and Virology. According to data from OpenAlex, Olaf Weber has authored 34 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 13 papers in Immunology and 9 papers in Virology. Recurrent topics in Olaf Weber's work include Immunotherapy and Immune Responses (8 papers), Poxvirus research and outbreaks (8 papers) and Virus-based gene therapy research (7 papers). Olaf Weber is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Poxvirus research and outbreaks (8 papers) and Virus-based gene therapy research (7 papers). Olaf Weber collaborates with scholars based in Germany, United States and New Zealand. Olaf Weber's co-authors include Siegfried Goldmann, Jürgen Stoltefuß, Karl Deres, Dieter Haebich, Astrid Friebe, Hans‐Dieter Volk, Angela Siegling, Helga Ruebsamen‐Waigmann, Helga Rübsamen‐Waigmann and Thomas Krämer and has published in prestigious journals such as Science, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Olaf Weber

34 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olaf Weber Germany 18 733 412 240 201 193 34 1.3k
Maria Seifer United States 19 1.2k 1.6× 868 2.1× 424 1.8× 95 0.5× 89 0.5× 39 1.5k
Marc P. Windisch South Korea 21 574 0.8× 565 1.4× 410 1.7× 114 0.6× 226 1.2× 57 1.6k
Isabelle Cannie France 12 1.1k 1.5× 991 2.4× 180 0.8× 80 0.4× 163 0.8× 17 1.9k
Tianlun Zhou United States 17 907 1.2× 675 1.6× 234 1.0× 89 0.4× 130 0.7× 33 1.3k
Magdeleine Hung United States 21 520 0.7× 315 0.8× 622 2.6× 532 2.6× 192 1.0× 38 1.4k
Kai Lin United States 25 919 1.3× 1.0k 2.5× 588 2.5× 200 1.0× 131 0.7× 50 2.0k
Kenneth Simmen Belgium 20 892 1.2× 753 1.8× 459 1.9× 56 0.3× 192 1.0× 39 1.6k
Paul Targett‐Adams United Kingdom 21 960 1.3× 1.2k 2.9× 187 0.8× 172 0.9× 148 0.8× 35 2.0k
Teresa I. Ng United States 26 1.4k 1.9× 1.1k 2.7× 661 2.8× 167 0.8× 158 0.8× 59 2.0k
Naina Barretto United States 10 627 0.9× 366 0.9× 836 3.5× 57 0.3× 398 2.1× 14 1.8k

Countries citing papers authored by Olaf Weber

Since Specialization
Citations

This map shows the geographic impact of Olaf Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olaf Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olaf Weber more than expected).

Fields of papers citing papers by Olaf Weber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olaf Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olaf Weber. The network helps show where Olaf Weber may publish in the future.

Co-authorship network of co-authors of Olaf Weber

This figure shows the co-authorship network connecting the top 25 collaborators of Olaf Weber. A scholar is included among the top collaborators of Olaf Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olaf Weber. Olaf Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Amini, Leila, Jaspal Kaeda, Olaf Weber, & Petra Reinke. (2024). Low-dose Interleukin-2 Therapy: Fine-tuning Treg in Solid Organ Transplantation?. Transplantation. 108(7). 1492–1508. 5 indexed citations
2.
Friebe, Astrid, Angela Siegling, & Olaf Weber. (2017). Inactivated Orf-virus shows disease modifying antiviral activity in a guinea pig model of genital herpesvirus infection. Journal of Microbiology Immunology and Infection. 51(5). 587–592. 10 indexed citations
3.
Weber, Olaf, et al.. (2015). AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B. PLoS ONE. 10(12). e0144383–e0144383. 18 indexed citations
4.
Urban, Andreas, Claudia Hirth‐Dietrich, Angela Siegling, et al.. (2013). Inactivated Orf Virus Shows Antifibrotic Activity and Inhibits Human Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Replication in Preclinical Models. PLoS ONE. 8(9). e74605–e74605. 18 indexed citations
5.
Hirth‐Dietrich, Claudia, Angela Siegling, Hans‐Dieter Volk, et al.. (2012). Inactivated Orf virus (Parapoxvirus ovis) elicits antifibrotic activity in models of liver fibrosis. Hepatology Research. 43(5). 535–546. 11 indexed citations
6.
Weber, Olaf, Andrew A. Mercer, Astrid Friebe, Percy A. Knolle, & Hans‐Dieter Volk. (2012). Therapeutic immunomodulation using a virus—the potential of inactivated orf virus. European Journal of Clinical Microbiology & Infectious Diseases. 32(4). 451–460. 28 indexed citations
7.
Heinig, Roland, Carsten Schmeck, C. Kohlsdorfer, et al.. (2011). Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein. British Journal of Clinical Pharmacology. 73(2). 210–218. 16 indexed citations
8.
9.
Vakalopoulos, Alexandros, Carsten Schmeck, Hilmar Bischoff, et al.. (2010). Chromanol derivatives—A novel class of CETP inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(1). 488–491. 17 indexed citations
10.
Schmeck, Carsten, Heike Gielen‐Haertwig, Alexandros Vakalopoulos, et al.. (2010). Novel tetrahydrochinoline derived CETP inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(5). 1740–1743. 19 indexed citations
11.
Weber, Olaf, et al.. (2010). Cholesteryl ester transfer protein and its inhibition. Cellular and Molecular Life Sciences. 67(18). 3139–3149. 26 indexed citations
12.
Schön, Margarete, Susanne Kneitz, Olaf Weber, et al.. (2008). KINK-1, a Novel Small-Molecule Inhibitor of IKKβ, and the Susceptibility of Melanoma Cells to Antitumoral Treatment. JNCI Journal of the National Cancer Institute. 100(12). 862–875. 48 indexed citations
13.
14.
Deres, Karl, Claus H. Schröder, Siegfried Goldmann, et al.. (2003). Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids. Science. 299(5608). 893–896. 418 indexed citations
15.
Schneider, E. M., Ina Menzl, Olaf Weber, & Hubert Hug. (2003). Differential calcium response in HeLa and HeLa-Fas cells by cytotoxic T lymphocytes. Biochemical and Biophysical Research Communications. 301(1). 159–166. 5 indexed citations
16.
Weber, Olaf, Angela Siegling, Astrid Friebe, et al.. (2003). Inactivated parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. Journal of General Virology. 84(7). 1843–1852. 47 indexed citations
17.
Weber, Olaf, Enno Hartmann, Karl Deres, et al.. (2002). Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Research. 54(2). 69–78. 141 indexed citations
18.
Weber, Olaf, Wolfgang Bender, Siegfried Goldmann, et al.. (2001). Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Research. 49(3). 179–189. 27 indexed citations
19.
Weber, Olaf. (2000). Novel Mouse Models for the Investigation of Experimental Drugs with Activity against Human Varicella-Zoster Virus. Antiviral chemistry & chemotherapy. 11(4). 283–290. 9 indexed citations
20.
Weber, Olaf, et al.. (1993). [Retroperitoneal benign schwannoma].. PubMed. 99(4). 189–91. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Seifer Breakdown of academic impact, for papers by Marc P. Windisch Breakdown of academic impact, for papers by Isabelle Cannie Breakdown of academic impact, for papers by Tianlun Zhou Breakdown of academic impact, for papers by Magdeleine Hung Breakdown of academic impact, for papers by Kai Lin Breakdown of academic impact, for papers by Kenneth Simmen Breakdown of academic impact, for papers by Paul Targett‐Adams Breakdown of academic impact, for papers by Teresa I. Ng Breakdown of academic impact, for papers by Naina Barretto
Rankless by CCL
2026